Development of a UV-Vis Method for Minoxidil Quantification in Compounded Capsules

August 2026 in “ Scientific Electronic Archives ”

João Eric Rocha de Oliveira, Roberta de Castro Vieira, Alana Mara Calou de Araújo, Linaldo Francisco da Silva Filho, Kamila Isabella Andrade de Souza, Antônio Rodolfo de Faria, Keyla Emanuelle Ramos de Holanda, Myla Lôbo de Souza, Maria Joanellys dos Santos Lima, Pedró José Rolim Neto, Maria José Cristiane Lima e Silva, Rosali Maria Ferreira da Silva

minoxidil alopecia UV-Vis spectrophotometric method compounded capsules quality control active ingredient compliance Rogaine

Studysummary This study evaluated a UV-Vis spectrophotometric method to measure minoxidil in compounded capsules from pharmacies in Pernambuco, Brazil, finding that while the formulations met weight criteria, most deviated significantly from declared minoxidil content, highlighting the need for robust quality control in compounded medicines.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on scientificelectronicarchives.org →

Discuss this study in the Community →

Research cited in this study

6 / 6 results

research The Use of Oral Dutasteride, Minoxidil, and Finasteride for Treating Endocrine Therapy-Induced Hair Loss from Breast Cancer Treatment: A Case Series Study

November 2025 in “JAAD Case Reports”

Oral dutasteride, minoxidil, and finasteride may help reduce hair loss in breast cancer survivors, but more research is needed.

research Low-Dose Oral Minoxidil During Chemotherapy: A Review of the Mechanism and Current Evidence

August 2025 in “Skin Appendage Disorders”

This review highlights that while low-dose oral minoxidil appears well-tolerated in cancer patients post-chemotherapy, its use during active chemotherapy has shown potential benefits but remains under investigation, with preclinical studies suggesting a protective effect against chemotherapy-induced alopecia.

research Characterization and Management of Adverse Events of Low-Dose Oral Minoxidil Treatment for Alopecia: A Narrative Review

March 2025 in “Journal of Clinical Medicine”

This study reviewed adverse events associated with low-dose oral minoxidil for treating alopecia, finding hypertrichosis and fluid retention as common, typically manageable side effects without needing treatment discontinuation.

research Quality Control In Compounded Minoxidil Solutions

December 2024 in “Brazilian Journal of Development”

This study evaluated the quality of 5% Minoxidil samples and found that only one out of three magistral formulations met acceptance criteria, highlighting the need for stricter quality control in custom pharmacy preparations to ensure their therapeutic efficacy.

research The Role of Minoxidil in the Treatment of Alopecia Areata: A Systematic Review and Meta-Analysis

December 2024 in “Journal of Clinical Medicine”

This study reported that both 5% topical and oral minoxidil achieved an 82% hair regrowth response rate in alopecia areata patients, but 5% topical minoxidil was more effective than lower concentrations.

research Efficacy and Safety of Low-Dose Oral Minoxidil in the Management of Androgenetic Alopecia

January 2024 in “Expert Opinion on Pharmacotherapy”

This source suggests that oral minoxidil could be a safe and effective treatment option for both female and male androgenetic alopecia, although it is currently used off-label.